demonstrated that ablation of GSDMD, the potential downstream effector of NLRP3, dramatically prevented or ameliorated NOMID-induced inflammatory symptoms and disease progression (25–27), suggesting a potential clinical translational value of GSDMD in CAPS. This evidence concerns the gene GSDMD and cryopyrin-associated periodic syndrome.